First Trust Nasdaq Pharmaceuticals ETF (FTXH)
| Assets | $14.74M |
| Expense Ratio | 0.60% |
| PE Ratio | 14.51 |
| Shares Out | 550,002 |
| Dividend (ttm) | $0.44 |
| Dividend Yield | 1.66% |
| Ex-Dividend Date | Jun 26, 2025 |
| Payout Frequency | Quarterly |
| Payout Ratio | 24.18% |
| Volume | 3,877 |
| Open | 26.48 |
| Previous Close | 26.46 |
| Day's Range | 26.44 - 26.57 |
| 52-Week Low | 23.29 |
| 52-Week High | 29.72 |
| Beta | 0.55 |
| Holdings | 50 |
| Inception Date | Sep 20, 2016 |
About FTXH
Fund Home PageThe First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is issued by First Trust.
Top 10 Holdings
54.21% of assets| Name | Symbol | Weight |
|---|---|---|
| Pfizer Inc. | PFE | 7.52% |
| Johnson & Johnson | JNJ | 7.36% |
| AbbVie Inc. | ABBV | 7.19% |
| Merck & Co., Inc. | MRK | 7.02% |
| Bristol-Myers Squibb Company | BMY | 6.27% |
| Viatris Inc. | VTRS | 3.86% |
| Gilead Sciences, Inc. | GILD | 3.86% |
| Amgen Inc. | AMGN | 3.76% |
| Biogen Inc. | BIIB | 3.71% |
| Zoetis Inc. | ZTS | 3.66% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 26, 2025 | $0.0892 | Jun 30, 2025 |
| Mar 27, 2025 | $0.0992 | Mar 31, 2025 |
| Dec 13, 2024 | $0.1304 | Dec 31, 2024 |
| Sep 26, 2024 | $0.1218 | Sep 30, 2024 |
| Jun 27, 2024 | $0.1284 | Jun 28, 2024 |
| Mar 21, 2024 | $0.0676 | Mar 28, 2024 |
Performance
FTXH had a total return of -2.57% in the past year, including dividends. Since the fund's inception, the average annual return has been 4.28%.
News
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...
Biotech Innovations Remain At Forefront
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...
Moving Beyond COVID In Biopharma
Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,...
Healthcare: A Wide Choice Of Large And Well-Established Companies
The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets...
ETF Spotlight: Pharmaceuticals driven higher by Pfizer
CNBC'S Morgan Brennan takes a look at pharmaceutical as Pfizer's positive vaccine news has led the sector higher.
